Abstract Number: 1636 • 2015 ACR/ARHP Annual Meeting
Clinical Benefit of 1-Year Certolizumab Pegol Treatment in MTX-Naïve, Early Rheumatoid Arthritis Patients Is Maintained after Discontinuation up to 1 Year
Background/Purpose: Efficacy and safety of certolizumab pegol (CZP) treatment in combination with optimized-dose MTX in Japanese MTX-naïve early rheumatoid arthritis (RA) patients (pts) with poor…Abstract Number: 2736 • 2015 ACR/ARHP Annual Meeting
Reduction of Disease Burden on Workplace and Household Productivity Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in DMARD-Naïve Patients with Active, Severe, Progressive Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is associated with work disability and lower employment rates (evidence shows 20–30% of pts are work disabled in the first 3…Abstract Number: 519 • 2015 ACR/ARHP Annual Meeting
In Indigenous North Americans at High Risk for RA Complement C5 Level Is Associated with ACPA Positivity and C5a with Transition to Synovitis Even after Correcting for in Vitro Complement Activation Found with Prolonged Sample Storage
Background/Purpose: Complement activation, a key component of innate immunity and activator of adaptive immunity has been linked to RA pathogenesis. Anti-citrullinated peptide antibody (ACPA) and…Abstract Number: 1638 • 2015 ACR/ARHP Annual Meeting
Early Response As a Predictor of Long-Term Remission in DMARD-Naïve Patients with Severe, Active and Progressive Rheumatoid Arthritis Treated with Certolizumab Pegol in Combination with Methotrexate
Background/Purpose: In established rheumatoid arthritis (RA), a lack of response to treatment with certolizumab pegol (CZP) at early timepoints is associated with a low probability…Abstract Number: 2741 • 2015 ACR/ARHP Annual Meeting
An Analysis of the Efficacy of Tofacitinib Monotherapy in MTX-Naïve Patients with Early RA Compared with Patients with Established RA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. In a Phase 3 study (ORAL Start; NCT01039688), tofacitinib monotherapy in MTX-naïve…Abstract Number: 2460 • 2014 ACR/ARHP Annual Meeting
Phospho-STAT1/3 and Gene Expression Measurement in Circulating CD4+ T Cells As Diagnostic Tools in Early Autoantibody-Negative Rheumatoid Arthritis
Background/Purpose Early diagnosis of rheumatoid arthritis (RA) improves outcomes but is challenging, particularly amongst anti-citrullinated peptide auto-antibody (ACPA) negative individuals. Previously we identified an IL-6…Abstract Number: 1402 • 2014 ACR/ARHP Annual Meeting
Parameters of Periodontitis Correlate with Anti-Citrullinated Protein Antibodies and P. Gingivalis Antibody Titers in Patients with Early or Chronic Rheumatoid Arthritis
Background/Purpose Emerging evidence suggests that periodontitis and periodontal pathogens, such as Porphyromonas gingivalis (Pg), may be an environmental trigger for rheumatoid arthritis (RA). We found…Abstract Number: 361 • 2014 ACR/ARHP Annual Meeting
Citrullinated 14-3-3η Antibodies Are Specific for Early and Established RA and Are Complementary to ACPA
Background/Purpose Citrullination is a post-translational modification whereby arginine (Arg) is deiminated by PAD enzymes to form citrulline (Cit). In RA, current ACPA assays measure the…Abstract Number: 2463 • 2014 ACR/ARHP Annual Meeting
Stromal Cell Markers Are Differentially Expressed in the Synovial Tissue of Patients with Early Arthritis
Background/Purpose Previous studies have shown increased expression of stromal markers in synovial tissue (ST) of patients with established rheumatoid arthritis (RA). Here, the expression of…Abstract Number: 1388 • 2014 ACR/ARHP Annual Meeting
Prevalence and Predictive Factors of Drug-Free and Sustained Remission in Patients with Early Arthritis
Background/Purpose : Early and sustained remission has become the ultimate goal in early arthritis patients. The aim of our study was to estimate the prevalence…Abstract Number: 360 • 2014 ACR/ARHP Annual Meeting
88% of Recent Onset Polyarthritis Patients Are Positive for 14-3-3η Markers and 14-3-3η Auto-Antibodies Inform a Favourable Prognosis
Background/Purpose The 14-3-3η protein has been described as a mechanistic marker that is detectable in serum during the very early stages of RA development. A…Abstract Number: 2417 • 2014 ACR/ARHP Annual Meeting
Is Remission Really Achievable in EARLY Rheumatoid Arthritis?
Background/Purpose: : to stress the need of routine use of US imaging in treat to target strategies aiming to achieve remission in early rheumatoid arthritis.…Abstract Number: 1383 • 2014 ACR/ARHP Annual Meeting
Disease Characteristics and RA Development in Undifferentiated Arthritis: A 2-Year Follow-up Study of 413 Patients with Arthritis of Less Than 16 Weeks Duration
Background/Purpose: Correct identification of the subset of patients with undifferentiated arthritis (UA) who will develop rheumatoid arthritis (RA) is important to enable initiation of appropriate…Abstract Number: 374 • 2014 ACR/ARHP Annual Meeting
IL-33 and Soluble ST2 Levels As Novel Predictors for Remission and Progression of Carotid Plaque in Early Rheumatoid Arthritis: A Prospective Study
Background/Purpose Clinical remission is achievable for patients with early rheumatoid arthritis (ERA). Identification of predictors for response of treatment may provide risk estimation and help…Abstract Number: 2381 • 2014 ACR/ARHP Annual Meeting
Adherence to a Treat-to-Target (T2T) Strategy in Early Rheumatoid Arthritis. Is It Feasible in Daily Clinical Practice?
Background/Purpose : The treat-to-target (T2T) strategy has become the new paradigm for the treatment of Rheumatoid Arthritis (RA); however the question is whether this strategy…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 18
- Next Page »